TIMP1 and Hepatic fibrosis: Except for TIMP1, noninvasive liver fibrosis markers had generally increased from baseline to weeks 4 and 8 (30–60 mg QD dosing period), before declining to near baseline levels at week 12 (100 mg QD dosing period) (Table 3, Figure 2c,d).